Outro, a New York-based neuroscience platform dedicated to the safe discontinuation of psychiatric medications, has successfully raised $7 million in a combined pre-seed and seed funding round. The investment marks a significant milestone in the emerging field of deprescribing, an area of healthcare that focuses on the supervised reduction or cessation of medications when they are no longer needed or are causing harm. The funding round saw participation from a diverse group of venture capital firms, including Listen Ventures, Cake Ventures, Jason Calacanis’s LAUNCH, Actions Capital, Hannah Grey Ventures, SemperVirens, Brock Recovery Group, and Pave Health Ventures. This influx of capital is earmarked for the expansion of Outro’s clinical network, the development of proprietary artificial intelligence tools for clinical decision support, and the broadening of the platform’s scope to include other medication classes such as benzodiazepines and GLP-1 agonists.
The emergence of Outro comes at a critical juncture in American healthcare, where the long-term use of psychiatric medications has reached historic levels. According to recent data, approximately one in six Americans—nearly 17% of the adult population—takes some form of antidepressant. While these medications are often essential for managing acute mental health crises, a growing body of research suggests that many patients remain on these drugs for years, or even decades, without a clear clinical pathway for eventual discontinuation. Outro aims to serve as the "off-ramp" for these patients, providing a science-based, medically supervised alternative to the "cold turkey" methods or linear tapering schedules that often lead to severe withdrawal symptoms and relapse.
The Growing Crisis of Long-Term Medication Dependency
The challenge of discontinuing psychiatric medications is not merely a matter of willpower but a complex physiological hurdle. Research conducted by Outro’s co-founder, Dr. Mark Horowitz, a clinical research fellow in psychiatry at University College London and a leading expert in deprescribing, indicates that four out of five long-term antidepressant users find it nearly impossible to stop their medication due to the severity of withdrawal symptoms. These symptoms can range from physical issues like "brain zaps," nausea, and insomnia to psychological distress including heightened anxiety and irritability, which are often misdiagnosed by clinicians as a relapse of the original condition.
This diagnostic confusion frequently leads to a "prescribing cascade," where new medications are introduced to treat the side effects or withdrawal symptoms of the initial drug. The lack of standardized protocols for tapering in the United States has left millions of patients in a state of indefinite dependency. While organizations like the National Institute for Health and Care Excellence (NICE) in the United Kingdom have updated their guidelines to recognize the severity of withdrawal and recommend gradual tapering, American clinical guidelines have historically lagged behind in providing specific, actionable steps for physicians to help patients transition off these medications.
The Science of Hyperbolic Tapering
At the core of Outro’s platform is the hyperbolic tapering method, a pharmacological approach designed to align medication reduction with the way drugs actually interact with the human brain. Traditional tapering methods often involve linear reductions—for example, reducing a dose by 5mg every two weeks. However, neuroscience research shows that the relationship between a drug dose and its effect on brain receptors is not linear but hyperbolic.
As a dose gets lower, the relative impact on brain receptor occupancy increases significantly. A small drop at a high dose might have a negligible effect on the brain, but the same 5mg drop at a very low dose can result in a massive shift in brain chemistry, triggering intense withdrawal. Outro’s platform utilizes this data to create personalized tapering plans that involve progressively smaller reductions as the patient nears a zero dose. This "soft landing" approach is designed to minimize physiological shocks and allow the central nervous system to gradually recalibrate.
To facilitate these precise, micro-dose reductions, Outro provides patients with access to compounded medications. Standard pharmaceutical manufacturing often produces fixed doses that are too large for the final stages of a hyperbolic taper. By utilizing specialized pharmacies to create customized, liquid, or micro-dose formulations, Outro ensures that patients can follow their personalized schedules with a level of precision that is currently unavailable through traditional retail pharmacies.
Strategic Use of Funding and Technological Integration
With the $7 million in new capital, Outro is poised to scale its operations and enhance its technological infrastructure. A primary focus of the company’s expansion is the recruitment and training of a specialized network of clinicians. Deprescribing is a nuanced skill set that requires a deep understanding of pharmacology and patient psychology. Outro’s clinicians are trained specifically in the hyperbolic method and in distinguishing between withdrawal symptoms and the return of underlying mental health conditions.
Furthermore, Outro is investing heavily in artificial intelligence to create a clinical decision support system. This AI-driven tool is intended to analyze patient data in real-time, allowing clinicians to adjust tapering schedules based on the individual’s unique physiological responses and reported symptoms. Brandon Goode, co-founder and CEO of Outro, emphasized that the goal is to make the process of getting off a medication as supported and scientifically rigorous as the process of starting one.
"We want getting off a medication to be as supported as getting on it—arguably even more," Goode stated. "Outro is the off-ramp that should have been built from the beginning."
Investor Confidence and Market Gap
The participation of prominent investors like Listen Ventures and Cake Ventures underscores a growing recognition within the venture capital community that the "mental health tech" boom of the last decade has largely focused on access to prescriptions, while neglecting the long-term management and eventual cessation of those same treatments. Ellen Wilcox, a partner at Listen Ventures, noted that Outro is filling a fundamental gap in the healthcare continuum.
"Outro is building the infrastructure, therapeutic options, and support for deprescribing, starting with antidepressants—a model we believe will become a standard part of modern healthcare," Wilcox said in a statement accompanying the funding announcement.
The market for Outro’s services extends beyond antidepressants. The company has signaled its intent to expand into other drug classes where dependency and withdrawal are significant concerns. This includes benzodiazepines, which carry a high risk of physical dependence and dangerous withdrawal syndromes; gabapentinoids, often used for chronic pain and anxiety; and GLP-1 agonists, the highly popular class of weight-loss and diabetes drugs. As patients achieve their health goals on GLP-1s, there is an increasing demand for "exit strategies" that allow them to maintain their health outcomes without remaining on expensive, injectable medications indefinitely.
A Global Perspective on Deprescribing
Dr. Mark Horowitz’s involvement brings a global academic perspective to Outro’s New York-based operations. Having personally experienced the challenges of antidepressant withdrawal, Horowitz has dedicated his career to bridging the gap between clinical practice and patient experience. He noted that while countries like the U.K. have begun to institutionalize tapering support, the United States remains a challenging environment for patients seeking to reduce their medication load.
"Yet in America, where antidepressant use is widespread, tapering support is very hard to come by, so millions of patients are left without support when they are ready to come off," Horowitz said. "As someone personally impacted by a lack of tapering guidance, I am proud to be building a service to bridge this gap."
The broader implications of Outro’s model suggest a shift toward more holistic, patient-centered psychiatric care. By providing the tools for safe discontinuation, the platform empowers patients to make informed decisions about their long-term health. It also addresses the economic burden of polypharmacy—the use of multiple medications by a single patient—which costs the U.S. healthcare system billions of dollars annually in unnecessary prescriptions and the treatment of drug-related adverse events.
Future Outlook and Healthcare Implications
As Outro begins to deploy its new capital, the healthcare industry will likely watch closely to see if the platform can successfully integrate with existing insurance networks and primary care providers. For deprescribing to become a "standard part of modern healthcare," as envisioned by its investors, it will require a shift in how medical success is measured—moving away from a model of indefinite symptom management toward one of physiological recovery and medication optimization.
The company’s focus on AI and data-driven tapering could also provide valuable insights into the long-term effects of psychiatric drugs, potentially influencing future drug development and prescribing habits. In an era where "precision medicine" is a buzzword, Outro is applying that precision to the end of the treatment lifecycle, ensuring that the "off-ramp" is just as carefully engineered as the "on-ramp."
Ultimately, Outro’s mission is to normalize the conversation around medication cessation. By combining specialized clinical expertise, personalized pharmacology, and advanced technology, the company seeks to provide a safe, sustainable path for millions of Americans who wish to transition to a life free from psychiatric medication, ensuring that the decision to stop a drug is as safe and informed as the decision to start it.
